Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance

Phase 2

Terminated

Conditions: Kidney Transplantation

Interventions: Biological: anti-thymocyte globulin
Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Total Body Irradiation
Drug: acetaminophen
Drug: diphenhydramine
Drug: methylprednisolone
Biological: bone marrow transplant
Drug: MESNA
Drug: mycophenolate mofetil
Drug: prednisone
Drug: filgrastim

First Posted Date: 2014-01-08

Last Posted Date: 2018-09-24

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 4

Registration Number: NCT02029638

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Phase 3

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Biospecimen Collection
Biological: Blinatumomab
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Daunorubicin
Drug: Daunorubicin Hydrochloride
Drug: Dexamethasone
Drug: Etoposide
Drug: Leucovorin Calcium
Procedure: Lumbar Puncture
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Pegaspargase
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine
Drug: Vincristine Sulfate
Procedure: X-Ray Imaging

First Posted Date: 2013-12-06

Last Posted Date: 2024-12-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 488

Registration Number: NCT02003222

Locations: 🇺🇸
Banner North Colorado Medical Center, Greeley, Colorado, United States
🇺🇸
Good Samaritan Hospital - Cancer Centers of Colorado, Lafayette, Colorado, United States
🇺🇸
Banner McKee Medical Center, Loveland, Colorado, United States

and more 545 locations

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Velcade
Drug: Pomalidomide
Drug: Dexamethasone
Drug: Melphalan
Drug: Thalidomide
Drug: Diphenhydramine
Drug: Prednisone
Drug: Acetaminophen
Drug: Carfilzomib
Drug: Montelukast
Drug: Lenalidomide

First Posted Date: 2013-12-03

Last Posted Date: 2025-01-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 240

Registration Number: NCT01998971

Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Dovitinib
Drug: Abiraterone Acetate
Drug: Prednisone

First Posted Date: 2013-11-26

Last Posted Date: 2019-03-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 4

Registration Number: NCT01994590

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer
Castration Resistant Prostate Cancer
Prostatic Neoplasms

Interventions: Drug: cabozantinib
Drug: abiraterone
Drug: prednisone

First Posted Date: 2013-11-26

Last Posted Date: 2015-02-20

Lead Sponsor: Exelixis

Target Recruit Count: 54

Registration Number: NCT01995058

Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients

Phase 4

Completed

Conditions: Prostate Cancer

Interventions: Drug: Enzalutamide
Drug: Placebo for Enzalutamide
Drug: Abiraterone
Drug: Prednisone

First Posted Date: 2013-11-26

Last Posted Date: 2023-09-18

Lead Sponsor: Pfizer

Target Recruit Count: 509

Registration Number: NCT01995513

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇦🇺
Box Hill Hospital, Box Hill, Victoria, Australia
🇧🇪
Universitaire Ziekenhuizen Leuven, Leuven, Belgium

and more 86 locations

A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma, Non Hodgkin

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Obinutuzumab
Drug: Polatuzumab Vedotin
Drug: Prednisolone
Drug: Prednisone
Drug: Rituximab

First Posted Date: 2013-11-25

Last Posted Date: 2023-03-14

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 85

Registration Number: NCT01992653

Locations: 🇫🇷
Hopital Henri Mondor, Unite Hemopathies lymphoides, Creteil, France
🇺🇸
Banner MD Anderson Cancer Center, Greeley, Colorado, United States
🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 8 locations